A drug trial, also called a clinical trial, is a carefully controlled research study that tests whether a new medication is safe and effective in people. Before any drug reaches a pharmacy shelf, it goes through years of testing in human volunteers, progressing through distinct phases that gradually expand from a handful of participants to thousands. The entire process from early lab discovery to market approval takes an average of about 10.5 years, with the clinical (human testing) portion alone averaging around 95 months.
What Happens Before Human Testing
Before a drug is ever given to a person, it spends years in preclinical development. Researchers first identify a compound that shows promise in laboratory tests, then study it in animal models to get early data on safety, how the body processes it, and whether it appears to work against a disease. This preclinical stage lasts roughly 31 months on average. Only after this data looks promising does a drug company submit an application to a regulatory agency like the FDA for permission to begin testing in humans.
The Four Phases of a Drug Trial
Phase 1: Safety and Dosage
The first time a drug is given to humans, it’s tested in a small group of 20 to 100 people, often healthy volunteers. The goal isn’t to cure anyone yet. Researchers are watching closely for side effects and figuring out safe dosage ranges: how much of the drug the body can tolerate, how it’s absorbed and processed, and what happens as the dose increases. Phase 1 trials typically last several months.
Phase 2: Does It Work?
If the drug clears Phase 1, it moves to a larger group of up to several hundred people who actually have the disease or condition being targeted. This is where researchers get the first real look at whether the drug does what it’s designed to do. They continue tracking side effects while refining the best dose and delivery method. Phase 2 trials can run from several months to two years.
Phase 3: Large-Scale Confirmation
Phase 3 is the pivotal stage. Between 300 and 3,000 volunteers with the disease participate, and the trial runs for one to four years. The larger group helps confirm effectiveness and reveals less common adverse reactions that might not show up in smaller studies. Regulatory agencies rely heavily on Phase 3 results when deciding whether to approve a drug. Most drugs that fail in clinical development fail here, either because they don’t outperform existing treatments or because side effects are too significant.
Phase 4: After Approval
Testing doesn’t stop once a drug hits the market. Phase 4 trials involve several thousand people and monitor the drug’s long-term safety and effectiveness in the real world, outside the controlled conditions of earlier phases. This matters because adverse reactions that occur in fewer than 1 in 3,000 to 5,000 patients are unlikely to be detected during pre-approval testing. Some side effects only emerge when millions of people start using a drug across different age groups, health backgrounds, and in combination with other medications. Safety monitoring continues for the entire life of a marketed drug, and new findings can lead to updated warning labels, dosage changes, or in rare cases, withdrawal from the market.
How Trials Are Designed to Reduce Bias
The gold standard in drug trials is the randomized, double-blind, placebo-controlled design. Each of those terms describes a specific layer of protection against bias.
Randomization means participants are assigned to the treatment group or the control group by chance, not by a doctor’s choice. This prevents researchers from consciously or unconsciously steering healthier patients into the drug group, which would skew results.
Double-blind means neither the participants nor the researchers interacting with them know who is receiving the real drug and who is receiving the placebo (an inactive substance that looks identical to the drug). This prevents expectations from influencing how people report symptoms or how doctors assess outcomes.
Placebo-controlled means the drug’s effects are measured against a group receiving no active treatment, isolating the drug’s true impact from the natural course of the disease or the psychological boost some people get simply from believing they’re being treated.
Not all trials use every one of these elements. Some conditions make placebos unethical, for example when an effective treatment already exists and withholding it could cause harm. In those cases, the new drug is compared against the current standard treatment instead.
How Participants Are Protected
Every drug trial involving human subjects must be reviewed and approved by an independent ethics board, known in the United States as an Institutional Review Board (IRB). These boards exist in over 80 countries worldwide. Their job is to evaluate whether a proposed study is ethically acceptable before a single participant enrolls. They check that risks are minimized and reasonable relative to the potential benefits, that participant selection is fair, and that adequate safeguards exist for privacy and confidentiality. An IRB has the authority to suspend or shut down a study if serious harm occurs or if researchers fail to follow the approved protocol.
Informed consent is another core protection. Before joining a trial, you must receive a clear explanation of the study’s purpose, expected duration, what procedures you’ll undergo, and which are experimental. You’re told about foreseeable risks, potential benefits, and any alternative treatments available to you. For trials involving more than minimal risk, you’re also told whether compensation or medical treatment is available if you’re injured. Participation is always voluntary. You can refuse to join without any penalty, and you can drop out at any time without losing access to care you’d otherwise receive.
Who Can Join a Drug Trial
Every trial has eligibility criteria, a specific list of characteristics participants must have (or must not have) to enroll. These criteria exist to ensure that participants are similar enough to each other that researchers can draw meaningful conclusions. Common factors include age range, the type and stage of disease, overall health, and what treatments a person has already tried. Some Phase 1 trials accept healthy volunteers with no medical condition at all, while later-phase trials typically require participants who have the specific disease being studied.
Eligibility criteria also protect participants from unnecessary risk. Someone with a liver condition, for example, might be excluded from a trial for a drug that’s processed by the liver, because the risk of harm would be disproportionately high.
How to Find a Drug Trial
ClinicalTrials.gov, run by the U.S. National Library of Medicine, is the largest public registry of clinical studies worldwide. You can search by condition, drug name, or location, and filter results by study status (recruiting, not yet recruiting, or completed), age, sex, and whether the trial accepts healthy volunteers. Each study listing includes an NCT number, a unique identifier in the format “NCT” followed by eight digits, which you can use to look up a specific trial directly or share with your doctor.
Searching for a trial doesn’t commit you to anything. Listings include contact information for the research team, and the screening process itself will determine whether you meet the eligibility criteria before any decision is made about participation.